

PRESS RELEASE

Contact: Matthew Sokol 203-573-2153

Chemtura Reports Third Quarter 2015 Financial Results

Third Quarter 2015 GAAP earnings from continuing operations and managed basis earnings from continuing operations of \$0.45 per diluted share

Core Segments deliver year-over-year improvement of \$29 million in operating income on a GAAP basis and \$27 million on a managed basis

PHILADELPHIA, PA–October 28, 2015–Chemtura Corporation, (NYSE/Euronext Paris: CHMT) (the "Company," "Chemtura," "We," "Us" or "Our") today announced financial results for the third quarter ended September 30, 2015. The Company also filed with the Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. For the third quarter of 2015, Chemtura reported net sales of \$444 million and net earnings from continuing operations on a GAAP basis of \$31 million, or \$0.45 per diluted share. Net earnings from continuing operations on a managed basis also were \$31 million, or \$0.45 per diluted share.

Third Quarter 2015 Financial Results

The discussion below includes financial information on both a GAAP and non-GAAP managed basis. We present managed basis financial information as management uses this information internally to evaluate and direct the performance of our operations and believes that managed basis financial information provides useful information to investors. A reconciliation of GAAP and managed basis as well as Core Segment financial information is provided in the supplemental schedules included in this release.

The following is a summary of the quarter ended September 30, 2015 unaudited financial results from continuing operations on a GAAP and managed basis (2014 data includes Chemtura AgroSolutions):

(In millions, except per share data)		Quart	ers	Ended - GAA	P	Quarters Ended - Managed Basis												
	Ser	otember 30,	Se	eptember 30,		Se	ptember 30,	Se	ptember 30,									
		2015		2014	% change		2015		2014	% change								
Net sales	\$	444	\$	558	(20%)	\$	434	\$	558	(22%)								
Operating income	\$	53	\$	35	51%	\$	45	\$	39	15%								
Earnings	\$	31	\$	15	107%	\$	31	\$	21	48%								
Earnings - per diluted share	\$	0.45	\$	0.17	(a)	\$	0.45	\$	0.23	96%								
Adjusted EBITDA						\$	70	\$	66	6%								

(a) - Changes greater than 150% are not shown.

CEO Remarks

"We delivered strong results this quarter," said Craig Rogerson, Chemtura's Chairman, President and Chief Executive Officer. "Adjusted EBITDA of our Core Segments grew \$27 million or 63% compared to the third quarter of last year and \$10 million or 17% sequentially. We also once again generated significant free cash flow in the quarter. We were able to achieve significant gains in profitability despite continued softness in sales volume in many areas, demonstrating the strength of our focused specialty chemical portfolio and the continued results from our cost reduction and commercial excellence initiatives," said Mr. Rogerson.

"Our Industrial Performance Products segment continued to benefit from lower raw material costs, which more than made up for lower revenues that were the result of overall lower pricing. Industrial Engineered Products posted impressive year-overyear improvements, driven by continued improvements in bromine and bromine-derivative pricing and improved manufacturing performance. Both segments experienced meaningful reductions in manufacturing and SG&A costs compared to the previous quarter and the third quarter of last year, demonstrating the success of our cost reduction initiatives," commented Mr. Rogerson. "Overall, we are proud of our results and our proven ability to create value for shareholders."

Third Quarter Core Segments Overview

We use the term "Core Segments" to describe our Industrial Performance Products, Industrial Engineered Products and Corporate segments only. Our Agrochemical Manufacturing segment contains the results of our on-going supply agreements with the purchaser of our Chemtura AgroSolutions business and the results of Chemtura AgroSolutions for periods prior to our sale of the business in November 2014.

(See tables that follow for a quantitative summary of components of change by segment between the third quarter of 2014, the second quarter of 2015 and the third quarter of 2015)

Industrial Performance Products ("IPP")

Our IPP segment reported lower net sales and higher operating income on both a GAAP and managed basis for the third quarter of 2015 compared with the third quarter of 2014. GAAP and managed basis net sales and operating income were slightly lower on a sequential basis.

The decline in third quarter net sales compared with the prior year is primarily the result of unfavorable changes in product mix within both our petroleum additive and urethane businesses as well as lower selling prices in our petroleum additives business as we continued to pass along lower input costs to our customers. Our IPP segment also experienced unfavorable foreign currency translation due to the strengthening of the U.S. dollar compared to last year. Sequentially, revenue was down slightly on flat volumes due primarily to unfavorable product mix in both IPP businesses, offset in part by increased sales in intermediates and synthetic lubricant products within our petroleum additives business.

Operating income on a GAAP and managed basis improved for the quarter despite lower volume and selling prices. The improvement year-over-year was due to lower raw material and manufacturing costs, which more than offset lower selling prices, lower volumes and unfavorable product mix. Sequentially, operating income was slightly lower as a result of the unfavorable product mix which was only partly offset by lower raw material and manufacturing costs. Both year-over-year and sequentially, the segment benefited from lower selling, general and administrative ("SG&A") costs which resulted from implementing the cost savings initiatives that we announced in the fourth quarter of 2014.

Industrial Engineered Products ("IEP")

Our IEP segment reported lower net sales and higher operating income on both a GAAP and managed basis compared with the third quarter of 2014 and the second quarter of 2015.

Net sales decreased year-over-year and sequentially predominately due to volume declines across many of our Great Lakes Solutions ("GLS") products, especially sales of furniture foam flame retardants, elemental bromine and, later in the third quarter, flame retardant products used in electronic applications largely reflecting customer inventory reductions. Sales prices for flame retardants used in electronic applications increased sequentially and compared to a year ago which offset the lower volumes. Net sales compared to the prior year were also impacted by the effect of foreign exchange translation as the U.S. dollar strengthened against foreign currencies beginning in late 2014.

Operating income in the third quarter of 2015 was higher compared to the prior quarter and a year ago primarily due to higher selling prices coupled with lower manufacturing and SG&A costs. SG&A continues to benefit from the cost reduction programs we announced in late 2014 and we are reflecting the full benefit of these initiatives in this quarter. Year-over-year, operating income benefited from a decrease in raw material costs, although raw material costs increased slightly when compared to the second quarter of 2015.

Corporate

Our Corporate segment expense decreased compared to the third quarter of 2014, but we note that our third quarter 2014 GAAP basis expense included \$7 million in costs related to the sale of our Chemtura AgroSolutions business. The reduction attributable to Chemtura AgroSolutions' sale related costs was offset by an increase in the accruals for employee benefit and management incentives due to our improved performance year-to-date. Sequentially, corporate expense decreased compared to the second quarter of 2015.

Agrochemical Manufacturing Segment

Net sales and operating income on a GAAP basis in our Agrochemical Manufacturing segment in the third quarter of 2015 were \$37 million and \$9 million, respectively. These results included \$10 million in net sales and operating profit related to the noncash amortization, net of accretion, of a below-market contract obligation that was recorded as part of the Chemtura AgroSolutions divestiture in 2014.

Income Taxes

Income tax expense on a GAAP basis was \$16 million in the third quarter of 2015 compared with \$12 million in the third quarter of 2014 and \$16 million in the second quarter of 2015. Through the third quarter of 2014, we continued to provide a full valuation allowance on our U.S. deferred tax assets and accordingly did not record an income statement tax provision on our U.S. income (losses) reflecting the related U.S. tax expense (benefit) as a reduction (increase) in the valuation allowance in those periods. Therefore, income tax expense for the quarter and nine months ended September 30, 2014 primarily represented income tax expense related to our foreign subsidiaries. Having released the valuation allowance on most of our U.S. deferred tax assets in the fourth quarter of 2014, income tax expense for the quarter and nine months ended September 30, 2015 included a full income tax provision on the income of both our foreign subsidiaries and our U.S. operations. In finalizing our 2014 U.S. income tax return, we concluded to claim certain U.S. income tax credits and deductions for 2014 and certain prior years in light of the change in our tax attributes in 2014. Based on a study concluded in the third quarter of 2015, those credits and deductions are greater than originally estimated. Our 2015 GAAP effective tax rate now reflects those changes to the prior estimate. We now anticipate our GAAP effective tax rate for the calendar year 2015 will be 32% with a range of 30% to 34% depending on any changes in the mix of income between U.S. and foreign jurisdictions or any additional discrete tax expenses or benefits.

On a managed basis, in 2013, we used an effective tax rate of 31%. In 2014, we elected to retain this rate until we were in a position to evaluate the effects of the sale of the Chemtura AgroSolutions business on the rate. In the first quarter of 2015, we completed our evaluation and based upon the forecast for the full year, we estimated our baseline managed basis tax rate at 28%. This rate is subject to fluctuations each quarter due to changes in our forecasted operating results of our continuing businesses, changes in the mix of income between U.S. and foreign jurisdictions and discrete items that are recorded in the periods identified. As of the September 30, 2015, we revised our managed basis rate for the inclusion of credits, deductions and return to provision adjustments discussed above but excluded those that relate to the divestiture of Chemtura AgroSolutions. We have also considered known changes in the mix of income between U.S. and foreign jurisdictions. Based on the adjustments to the effective rate discussed above we now estimate that our managed basis tax rate for the full year will be 23%. Due to the reduction of the tax rate from that used for the second quarter ended June 30, 2015, the resulting tax provision for the third quarter of 2015 is lower than the full year rate. We anticipate that the managed basis effective tax rate for the full year of 2015 may range from 21% to 25%. Excluding the adjustments to our rate for the credits, deductions and return to provision items, our estimated base line managed basis tax rate continues to be 28%.

Cash income taxes paid (net of refunds) for the third quarter of 2015, the third quarter of 2014 and the second quarter of 2015 were \$12 million, \$18 million and \$2 million, respectively.

Other Highlights

• Net cash provided by operating activities for the third quarter of 2015 was \$48 million as compared with net cash provided by operating activities of \$9 million and \$53 million for the third quarter of 2014 and second quarter of 2015, respectively.

- In the third quarter of 2015, we repurchased 0.7 million shares of common stock at a cost of \$18 million. As of September 30, 2015, the remaining authorization under our share repurchase program was approximately \$180 million.
- Capital expenditures for the third quarter of 2015 were \$21 million, compared to \$30 million in the third quarter of 2014 and \$19 million in the second quarter of 2015. The year-over-year decrease primarily related to lower spending on major capital projects at our Nantong, China facility, somewhat offset by an increase in capital spend at our DayStar facility in Hyeongok, South Korea.
- Our total debt was \$517 million as of September 30, 2015 compared with \$574 million as of December 31, 2014. The decrease was primarily due to a repayment of \$42 million on our Term Loan and a \$15 million repayment of our China Bank Facility.
- Cash and cash equivalents were \$317 million compared with \$392 million as of December 31, 2014. The decrease was primarily the result of repurchases of shares of common stock under our share repurchase program and debt repayments, partially offset by net proceeds of \$54 million from the sale of the Platform Specialty Products Corporation common stock during the second quarter of 2015.

Outlook

"We don't anticipate any significant changes in the fourth quarter to the lackluster demand environment we have seen in a number of our businesses during 2015. Nevertheless, we expect to continue to deliver year-over-year improvement in profitability," said Mr. Rogerson. "For our IEP business, we expect to continue to benefit from the improved bromine pricing we secured in recent months. Our contracted supply of bromine from Israel should return to full rates in the fourth quarter, which will help offset any headwinds in IEP. For clear brine fluids, it is likely that the steady demand we have seen will continue through the fourth quarter, but we still caution that a downturn is possible given lower oil prices reducing investment in exploration. For IPP, we have historically seen year-end customer destocking of certain petroleum additive products, which will result in modest reduction in profitability sequentially, but we still expect to deliver year-over-year improvement," commented Mr. Rogerson.

"Despite general softness in volumes," he added, "we remain committed to meet our 2015 Adjusted EBITDA targets that we first set out on our Investor Day in February," said Mr. Rogerson.

Third Quarter Earnings Q&A Teleconference

Copies of this release will be available on the Investor Relations section of our website at <u>www.chemtura.com</u>. We will host a teleconference to review these results at 2:00 p.m. (EDT) on Wednesday, October 28, 2015. Interested parties are asked to dial in approximately 10 minutes prior to the start time. The call-in number for U.S. based participants is (877) 633-3602 and for all other participants is (404) 665-9523. The conference ID code is 14708355.

Replay of the call will be available for thirty days, starting at 5 p.m. (EDT) on Wednesday, October 28, 2015. To access the replay, call toll-free (855) 859-2056, (800) 585-8367, or (404) 537-3406, and enter access code 14708355. An audio webcast of the call can be accessed via the link below during the time of the call:

http://edge.media-server.com/m/p/jfo89ife

Chemtura Corporation, with 2014 net sales of \$2.2 billion, is a global manufacturer and marketer of specialty chemicals. Additional information concerning us is available at <u>www.chemtura.com</u>.

Managed Basis Financial Measures

The information presented in this press release and in the attached financial tables includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States ("GAAP"). We believe that such managed basis financial measures provide useful information to investors and may assist them in evaluating our underlying performance and identifying operating trends. In addition, management uses these managed basis financial measures internally to allocate resources and evaluate the performance of our operations.

Our managed basis financial measures consist of adjusted results of operations that exclude certain expenses, gains and losses that may not be indicative of our core operations. Excluded items include costs associated with facility closures, severance and related

costs; gains and losses on the sale of businesses and assets; increased depreciation due to the change in useful life of assets under restructuring programs; unusual and non-recurring settlements; accelerated recognition of asset retirement obligations: impairment charges; changes in our pension plans as a result of dispositions, merger or significant plan amendments; the release of cumulative translation adjustments upon the complete or substantial liquidation of any majority-owned entity; the recognition of the fair value, net of accretion, of any significant below-market contractual obligations and the costs associated with the sale of our Chemtura AgroSolutions business in prior periods that was not included in the gain on sale of business. They also include the computation of Adjusted EBITDA. In addition to the managed basis financial measures discussed above, we have applied a managed basis effective income tax rate to our managed basis income before taxes. Reconciliations of these managed basis financial measures to their most directly comparable GAAP financial measures are provided in the attached financial tables.

While we believe that such measures are useful in evaluating our performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these managed basis financial measures may differ from similarly titled managed basis financial measures used by other companies and may not provide a comparable view of our performance relative to other companies in similar industries.

Forward-Looking Statements

This earnings press release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including our actions that will drive earnings growth, demand for our products and expectations for growth are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, potentially inaccurate assumptions and other factors, some of which are beyond our control and difficult to predict. If known or unknown risks materialize, or should underlying assumptions prove inaccurate, our actual results could differ materially from past results and from those expressed in forward-looking statements. Important factors that could cause our results to differ materially from those expressed in forward-looking statements include, but are not limited to, economic, business, competitive, political, regulatory, legal and governmental conditions in the countries and regions in which we operate. These factors are discussed more fully in the reports we file with the Securities and Exchange Commission, particularly our latest annual report on Form 10-K. We assume no obligation to provide revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

Index of Financial Statements and Schedules

	Page
GAAP and Managed Basis Condensed Consolidated Statements of Operations (Unaudited) -	
Quarters ended September 30, 2015, June 30, 2015 and September 30, 2014	<u>7</u>
GAAP and Managed Basis Segment Net Sales, Operating Income and Adjusted EBITDA (Unaudited) -	
Quarters ended September 30, 2015, June 30, 2015 and September 30, 2014	<u>8</u>
Condensed Consolidated Balance Sheets - September 30, 2015 (Unaudited) and December 31, 2014	<u>9</u>
Condensed Consolidated Statements of Cash Flows and Supplemental Data (Unaudited) -	
Quarters ended September 30, 2015, June 30, 2015 and September 30, 2014	<u>10</u>
Major Factors Affecting Managed Basis Net Sales and Operating Results (Unaudited) -	
Quarter ended September 30, 2015 versus September 30, 2014 and June 30, 2015	<u>11</u>
GAAP and Managed Basis Condensed Consolidated Statements of Operations (Unaudited) -	
Quarters ended September 30, 2015, June 30, 2015 and September 30, 2014	<u>12</u>
GAAP and Managed Basis Segment Net Sales and Operating Income (Unaudited) -	
	12
Quarters ended September 30, 2015, June 30, 2015 and September 30, 2014	<u>13</u>

-

Condensed Consolidated Statements of Operations (Unaudited)

(In millions, except per share data)

	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$												
											September 30, 2014		
						(a)					(a)		
Net sales	\$	444	\$	464	\$	558	\$	434	\$	454	\$ 558		
Cost of goods sold		327		350		424		327		350	423		
Gross profit		117		114		134		107		104	135		
Gross profit %		26 %	6	25%	6	24%		25 %	ó	23%	24%		
Selling, general and administrative		36		41		65		36		41	62		
Depreciation and amortization		22		24		24		22		23	24		
Research and development		4		6		10		4		6	10		
Facility closures, severance and related costs		1		—		—				—	—		
Loss on sale of business		1				—		—		_	—		
Equity income								—			—		
Operating income		53						45			39		
Interest expense		(7)		(8)		(12)		(7)		(8)	(12)		
Other income (expense), net		1		(2)		4		1		(2)	4		
Earnings from continuing operations before income taxes		47		34		27		39		25	31		
Income tax expense		(16)		(16)		(12)		(8)		(5)	(10)		
Earnings from continuing operations	\$	31	\$	18	\$	15	\$	31	\$	20	\$ 21		
Per share information:													
Earnings from continuing operations - Basic	\$	0.46	\$	0.27	\$	0.17	\$	0.46	\$	0.30	\$ 0.23		
Earnings from continuing operations - Diluted	\$	0.45	\$	0.26	\$	0.17	\$	0.45	\$	0.29	\$ 0.23		
Weighted average shares outstanding - Basic		67.5		67.6		89.4		67.5		67.6	89.4		
Weighted average shares outstanding - Diluted	_	68.3		68.5		90.7	_	68.3		68.5	90.7		
Comparison versus June 30, 2015:													
% change in net sales		(4)%	0					(4)%	, 0				
% change in operating income		20 %	ó					29 %	ó				
Comparison versus September 30, 2014:													
% change in net sales		(20)%	ó					(22)%	Ó				
% change in operating income		51 %	ó					15 %	ó				

(a) - The Chemtura AgroSolutions business was sold in November 2014. Subsequent to that date, the activity in this segment reflects on-going supply agreements with Platform Specialty Products, and therefore, the results in the prior periods are not comparable to the current period.

Segment Net Sales, Operating Income and Adjusted EBITDA (Unaudited)

(In millions)

	GAAP	- Quarters H	Ende	ed	Μ	Ianaged I	asis - Quarters Ended			
	tember , 2015	June 30, 2015		ptember 60, 2014		otember), 2015	June 30, 2015	Septer 30, 2		
NET SALES	 									
Petroleum additives	\$ 156	\$ 158	\$	169	\$	156	\$ 158	\$	169	
Urethanes	70	72		78		70	72		78	
Industrial Performance Products	226	230		247		226	230		247	
Bromine based & related products	144	158		157		144	158		157	
Organometallics	37	39		41		37	39		41	
Industrial Engineered Products	181	197		198		181	197		198	
Agrochemical Manufacturing (a)	37	37		113		27	27		113	
Total net sales	\$ 444	\$ 464	\$	558	\$	434	\$ 454	\$	558	
OPERATING INCOME										
Industrial Performance Products	\$ 37	\$ 38	\$	28	\$	37	\$ 38	\$	28	
Industrial Engineered Products	24	15		5		25	16		6	
Agrochemical Manufacturing (a)	9	10		20		(1)			20	
Segment operating income	70	63		53		61	54		54	
General corporate expense, including amortization	 (15)	(19))	(18)		(16)	(19))	(15)	
Facility closures, severance and related costs	(1)	—		_		_	—			
Loss on sale of business	(1)	_		_		_	_		_	
Total operating income	\$ 53	\$ 44	\$	35	\$	45	\$ 35	\$	39	
Adjusted EBITDA by Segment:										
Industrial Performance Products					\$	44	\$ 46	\$	35	
Industrial Engineered Products						36	28		17	
General corporate expense						(10)	(14))	(9)	
Core segments Adjusted EBITDA						70	60		43	
Agrochemical Manufacturing (a)						_	1		23	
Adjusted EBITDA					\$	70	\$ 61	\$	66	

(a) - The Chemtura AgroSolutions business was sold in November 2014. Subsequent to that date, the activity in this segment reflects on-going supply agreements with Platform Specialty Products, and therefore, the results in the prior periods are not comparable to the current period.

Condensed Consolidated Balance Sheets

(In millions)

Accounts receivable, net229251Inventories, net316329Other current assets147238Assets held for sale—6Total current assets1,0091,216NON-CURENT ASSETS668704Goodwill167172Intangible assets, net8999Deferred tax asset - non-current292313Other assets162163Total sexts\$2,387S 2,387\$2,667LIABILITIES AND EQUITY138146Accounts payable138146Account payable147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES382405Don-current helt care liabilities277318Below market contract obligation - no-current155185Deferred tax liability - non-current1725Other liabilities277318Deferred tax liability - non-current1725Other liabilities112124		Septeml	ber 30, 2015	Decem	ber 31, 2014
CURRENT ASSETS Cash and cash equivalents \$ 317 \$ 922 Accounts receivable, net 229 251 Inventories, net 316 329 Other current assets 147 238 Assets held for sale — 6 Total current assets 147 238 NON-CURRENT ASSETS — 668 Property, plant and equipment, net 668 704 Goodwill 167 172 Intangible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets <u>\$ 2,387</u> <u>\$ 2,667</u> LIABILITIES AND EQUITY		(Una	audited)		
S 317 S 392 Accounts receivable, net 229 251 Inventories, net 316 329 Other current assets 147 238 Assets held for sale — 6 Total current assets 1,009 1,216 NON-CURRENT ASSETS — 6 Property, plant and equipment, net 668 704 Goodwill 167 172 Intangible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets \$ 2,387 \$ 2,667 LIABILITIES AND EQUITY	ASSETS				
Accounts receivable, net 229 251 Inventories, net 316 329 Other current assets 147 238 Assets held for sale — 6 Total current assets 1,009 1,216 NON-CURRENT ASSETS — 6 Property, plant and equipment, net 668 704 Goodwill 167 172 Intargible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets § 2,387 § 2,667 LIABILITIES AND EQUITY CURRENT LIABILITIES 5 18 466 Accounts payable 138 146 46 47 170 Below market contract obligation - current 38 382 405 405 NON-CURRENT LIABILITIES	CURRENT ASSETS				
Inventories, net 316 329 Other current assets 147 238 Assets held for sale — 6 Total current assets 1,009 1,216 NON-CURENT ASSETS 167 172 Property, plant and equipment, net 668 704 Goodwill 167 172 Intangible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets \$ 2,387 \$ 2,667 LIABILITIES AND EQUITY	Cash and cash equivalents	\$	317	\$	392
Other current assets147238Assets held for sale—6Total current assets1,0091,216NON-CURRENT ASSETS6704Property, plant and equipment, net668704Goodwill167172Intangible assets, net8999Deferred tax asset - non-current292313Other assets162163Total Assets§2,387§CURRENT LIABILITIES\$42\$Short-term borrowings\$42\$Accounts payable138146Accruct expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current155185Deferred tax liability - non-current1724Total LEVITY9691,054	Accounts receivable, net		229		251
Assets held for sale $-$ 6Total current assets1,0091,216NON-CUREENT ASSETS704Property, plant and equipment, net668704Goodwill167172Intangible assets, net8999Deferred tax asset - non-current292313Other assets162163Total Assets§ 2,387§ 2,667LIABILITIES AND EQUITYCURRENT LIABILITIESShort-term borrowings\$ 42\$ 18Accounts payable138146Accrued expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale-9Total current liabilities382405NON-CURRENT LIABILITIES556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total LEQUITY9691,054	Inventories, net		316		329
Total current assets 1,009 1,216 NON-CURRENT ASSETS 668 704 Goodwill 167 172 Intangible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets \$ 2,387 \$ 2,667 LIABILITIES AND EQUITY CURRENT LIABILITIES \$ 188 146 Accounts payable 138 146 17 170 Below market contract obligation - current 38 38 38 Income taxes payable 17 24 405 NON-CURRENT LIABILITIES 382 405 NON-corract obligation - current 38 38 Income taxes payable 17 24 Liabilities held for sale — 9 Total current liabilities 382 405 NON-CURRENT LIABILITIES	Other current assets		147		238
NON-CURRENT ASSETS Property, plant and equipment, net 668 704 Goodwill 167 172 Intangible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets \$ 2,387 \$ 2,667 LIABILITIES AND EQUITY CURRENT LIABILITIES 5 2,667 Short-term borrowings \$ 42 \$ 18 Accounts payable 138 146 147 170 Below market contract obligation - current 38 388 38 38 Income taxes payable 17 24 24 145 170 Deferm debt - 9 9 104 145 155 188 Income taxes payable 17 24 145 155 188 166 167 17 24 Liabilities held for sale - 9 104 145 155 185 165 185 165 185 166 165 185 165	Assets held for sale		_		6
Property, plant and equipment, net 668 704 Goodwill 167 172 Intangible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets \$ 2,387 \$ 2,667 LIABILITIES AND EQUITY \$ 18 CURRENT LIABILITIES \$ 18 Short-term borrowings \$ 42 \$ 18 Accounts payable 138 146 Accrued expenses 147 170 Below market contract obligation - current 38 38 Income taxes payable 17 24 Liabilities held for sale 9 Total current liabilities 382 405 NON-CURRENT LIABILITIES 9 Long-term debt 475 556 Pension and post-retirement health care liabilities 277 318 Below market contract obligation - non-current 155 185 Deferred tax liability - non-current 17 25 Other liabilities 112 124 <td>Total current assets</td> <td></td> <td>1,009</td> <td></td> <td>1,216</td>	Total current assets		1,009		1,216
Intangible assets, net 167 172 Intangible assets, net 89 99 Deferred tax asset - non-current 292 313 Other assets 162 163 Total Assets \$ 2,387 \$ 2,667 LIABILITIES AND EQUITY CURRENT LIABILITIES \$ Short-term borrowings \$ 42 \$ 18 Accounts payable 138 146 Accrued expenses 147 170 Below market contract obligation - current 38 38 Income taxes payable 17 24 Liabilities held for sale — 9 Total current liabilities 382 405 NON-CURRENT LIABILITIES 17 24 Liabilities held for sale — 9 Total current liabilities 277 318 Below market contract obligation - non-current 155 185 Deferred tax liability - non-current 17 25 Other liabilities 112 124 Total liabilities 112 124 Total liabilities 17 25	NON-CURRENT ASSETS				
Intangible assets, net8999Deferred tax asset - non-current292313Other assets162163Total Assets\$ 2,387\$ 2,667LIABILITIES AND EQUITYCURRENT LIABILITIESShort-term borrowings\$ 42\$ 18Accounts payable138146Accrued expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES175516Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total LEQUITY9691,054	Property, plant and equipment, net		668		704
Deferred tax asset - non-current292313Other assets162163Total Assets\$2,387\$ LIABILITIES AND EQUITY CURRENT LIABILITIESShort-term borrowings\$42\$18Accounts payable138146Accrued expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES155185Deferred tax liability - non-current155185Deferred tax liabilities217318Below market contract obligation - non-current155185Other liabilities217318Total LEQUITY9691,054	Goodwill		167		172
Other assets162163Total Assets\$2,387\$2,667LIABILITIES AND EQUITYCURRENT LIABILITIESShort-term borrowings\$42\$18Accounts payable138146Accured expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current155185Deferred tax liabilities112124Total liabilities112124Total LEQUITY9691,054	Intangible assets, net		89		99
Total Assets\$2,387\$2,667LIABILITIES AND EQUITYCURRENT LIABILITIESShort-term borrowings\$42\$18Accounts payable138146Accrued expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES382405Long-term debt475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY9691,054	Deferred tax asset - non-current		292		313
LIABILITIES AND EQUITYCURRENT LIABILITIESShort-term borrowings\$ 42\$ 18Accounts payable138146Accrued expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES17556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY9691,054	Other assets		162		163
CURRENT LIABILITIESShort-term borrowings\$42\$18Accounts payable138146Accrued expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES382405Long-term debt475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities112124Total LEQUITY9691,054	Total Assets	\$	2,387	\$	2,667
Short-term borrowings \$ 42 \$ 18 Accounts payable 138 146 Accrued expenses 147 170 Below market contract obligation - current 38 38 Income taxes payable 17 24 Liabilities held for sale — 9 Total current liabilities 382 405 NON-CURRENT LIABILITIES 382 405 Long-term debt 475 556 Pension and post-retirement health care liabilities 277 318 Below market contract obligation - non-current 155 185 Deferred tax liability - non-current 17 25 Other liabilities 112 124 Total liabilities 1,418 1,613 TOTAL EQUITY 969 1,054	LIABILITIES AND EQUITY				
Accounts payable 138 146 Accrued expenses 147 170 Below market contract obligation - current 38 38 Income taxes payable 17 24 Liabilities held for sale — 9 Total current liabilities 382 405 NON-CURRENT LIABILITIES 382 405 Long-term debt 475 556 Pension and post-retirement health care liabilities 277 318 Below market contract obligation - non-current 155 185 Deferred tax liability - non-current 17 25 Other liabilities 112 124 Total liabilities 1,418 1,613 TOTAL EQUITY 969 1,054	CURRENT LIABILITIES				
Accrued expenses147170Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES382405Long-term debt475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY969	Short-term borrowings	\$	42	\$	18
Below market contract obligation - current3838Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES382405Long-term debt475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY969	Accounts payable		138		146
Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY969	Accrued expenses		147		170
Income taxes payable1724Liabilities held for sale—9Total current liabilities382405NON-CURRENT LIABILITIES475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY969	Below market contract obligation - current		38		38
Total current liabilities382405NON-CURRENT LIABILITIESLong-term debt475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY969	Income taxes payable		17		24
NON-CURRENT LIABILITIESLong-term debt475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY969	Liabilities held for sale		_		9
Long-term debt475556Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY9691,054	Total current liabilities		382		405
Pension and post-retirement health care liabilities277318Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY9691,054	NON-CURRENT LIABILITIES				
Below market contract obligation - non-current155185Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY9691,054	Long-term debt		475		556
Deferred tax liability - non-current1725Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY9691,054	Pension and post-retirement health care liabilities		277		318
Other liabilities112124Total liabilities1,4181,613TOTAL EQUITY9691,054	Below market contract obligation - non-current		155		185
Total liabilities1,4181,613TOTAL EQUITY9691,054	Deferred tax liability - non-current		17		25
TOTAL EQUITY 969 1,054	Other liabilities		112		124
	Total liabilities		1,418		1,613
	TOTAL FOULTY		969		1 054
	-	\$		\$	-

Condensed Consolidated Statements of Cash Flows and Supplemental Data (Unaudited)

(In millions)

			Qua	rters Ended	
Increase (decrease) to cash		ember 30, 2015	Jun	e 30, 2015	September 30, 2014
					(a)
Condensed Consolidated Statements of Cash Flows (Unaudited)					
Net cash provided by operating activities	\$	48	\$	53	
Net cash (used in) provided by investing activities		(21)		40	(23)
Net cash used in financing activities		(18)		(32)	(66)
Effect of exchange rates on cash and cash equivalents		(1)		3	(10)
Change in cash and cash equivalents		8		64	(90)
Cash and cash equivalents at beginning of period		309		245	235
Cash and cash equivalents at end of period	\$	317	\$	309	\$ 145
Supplemental cash flow data:					
Changes in accounts receivable	\$	33	\$	(2)	\$ 7
Changes in inventory	\$	(11)		(<i>z</i>) 7	
Changes in accounts payable	\$	(11)		(7)	· ()
Changes in pension and post-retirement health care liabilities	\$	(18)		(7)	
Net proceeds from divestments			\$	5	\$ 7
Sale of Platform shares			\$	54	
Capital expenditures	\$	(21)	\$	(19)	\$ (30)
Common shares acquired	\$	(18)	\$	_	\$ (70)
Income tax payments - net of refunds	\$	(12)	\$	(2)	\$ (18)
Interest payments	\$	(14)	\$	(2)	\$ (20)
		As of			
	-	ember 30,			
Capitalization data:		2015	_		
Total debt	\$	517	-		
Cash and cash equivalents	\$	317			
Net Debt (Total debt less Cash and cash equivalents)	\$	200			
Shore Damashasa Dramana		hares	C	4 of channe	Remaining
Share Repurchase Program:	pu	chased	Cos	t of shares	Authorization
October 2014 and August 2015 authorizations		10 7	¢		\$ 650 • 220
4Q 2014 Share Purchases		13.7	\$	330	
Nine months ended September 30, 2015 Share Purchases		5.8	\$	140	\$ 180

(a) - Includes activity related to the Chemtura AgroSolutions business that was sold in November 2014.

Major Factors Affecting Managed Basis Net Sales and Operating Results (Unaudited)

(In millions)

Net Sales - Managed Basis (a)	Indus Perfori Prod	nance	Industrial Engineered Products	Subtotal Core Segments	Agrochemical Manufacturing	Total
Quarter Ended September 30, 2014	\$	247 \$	198		\$ 113	\$ 558
Changes in selling prices		(8)	6	(2)		(2)
Unit volume and mix		(6)	(18)	(24)	—	(24)
Foreign currency		(7)	(5)	(12)	—	(12)
Divestiture		—		_	(86)	(86)
Quarter Ended September 30, 2015	\$	226 \$	181	\$ 407	\$ 27	\$ 434
Quarter Ended June 30, 2015	\$	230 \$	197	\$ 427	\$ 27	\$ 454
Changes in selling prices		(1)	2	1	—	1
Unit volume and mix		(3)	(18)	(21)		(21)
Quarter Ended September 30, 2015	\$	226 \$	181	\$ 407	\$ 27	\$ 434
				-		

Operating Income - Managed Basis (a) (b)	Industrial Performance Products	Industrial Engineered Products	General corporate expense	Subtotal Core Segments	Agrochemical Manufacturing	Total
Quarter Ended September 30, 2014	\$ 28	\$ 6	\$ (15)	\$ 19 S	\$ 20 \$	5 39
Price over raw materials	9	8	—	17	—	17
Unit volume and mix	(5)	(3)	—	(8)	—	(8)
Foreign currency	1		—	1	—	1
Divestitures	—		—	—	(22)	(22)
Manufacturing cost and absorption	1	10	—	11		11
Distribution cost	(1)	2	—	1	—	1
Depreciation and amortization expense			1	1	1	2
SGA&R	5	4	(4)	5	—	5
Other	(1)	(2)	2	(1)		(1)
Quarter Ended September 30, 2015	\$ 37	\$ 25	\$ (16)	\$ 46	\$ (1) \$	S 45
		• • • •	* (10)		•	
Quarter Ended June 30, 2015	\$ 38	\$ 16	\$ (19)		\$ _ \$	
Price over raw materials	—	1		1	—	1
Unit volume and mix	(3)	(1)		(4)		(4)
Foreign currency	1	—	—	1	—	1
Manufacturing cost	1	6	—	7	_	7
Depreciation and amortization expense	_	_	1	1	_	1
SGA&R	1	2	2	5		5
Other	(1)	1	—	—	(1)	(1)
Quarter Ended September 30, 2015	\$ 37	\$ 25	\$ (16)	\$ 46	\$ (1) \$	6 45

(a) - See tables that follow for a reconciliation of Net Sales and Operating Income to GAAP.

(b) - See tables that follow for a reconciliation to Adjusted EBITDA. Adjusted EBITDA excludes depreciation and amortization expense and share-based compensation expense from Operating Income on a Managed Basis.

CHEMTURA CORPORATION GAAP and Managed Basis Condensed Consolidated Statements of Operations (Unaudited) (In millions, except per share data)

	Qua	arter l	End	ed Septemb	er 3	0, 2015	Qua	rte	er ended June	30, 2	2015	Qu	arter	Endeo	d Septem	ber 3	0, 2014
	GA	ААР		Managed Basis ljustments	M	anaged Basis	GAAP		Managed Basis Adjustments	M	anaged Basis	G	AAP		anaged Basis ustments	М	anaged Basis
Net sales	\$	444	\$	(10)	\$	434	\$ 464	\$	6 (10)	\$	454	\$	558	\$		\$	558
Cost of goods sold		327		_		327	350		_		350		424		(1)		423
Gross profit		117		(10)		107	114		(10)		104	-	134		1		135
Gross profit %		26%	Ď			25%	25%	ó			23%		24%	6			24%
Selling, general and administrative		36		—		36	41		—		41		65		(3)		62
Depreciation and amortization		22		—		22	24		(1)		23		24		—		24
Research and development		4		_		4	6		_		6		10		_		10
Facility closures, severance and related costs		1		(1)		_	_		—		_		—		_		—
Loss on sale of business		1		(1)			—		_		—		—		_		—
Equity income		_		_		_	(1)		—		(1)				_		_
Operating income		53		(8)		45	44		(9)		35	-	35		4		39
Interest expense		(7)		_		(7)	(8)		_		(8)		(12)		_		(12)
Other income (expense), net		1		_		1	(2)		_		(2)		4		_		4
Earnings from continuing operations before income taxes		47		(8)		39	34		(9)		25		27		4		31
Income tax expense		(16)		8		(8)	(16)		11		(5)		(12)		2		(10)
Earnings from continuing operations	\$	31	\$	_	\$	31	\$ 18	\$	5 2	\$	20	\$	15	\$	6	\$	21
Per share information:																	
Earnings from continuing operations - Basic		0.46	-		\$	0.46	\$ 0.27	-		\$	0.30	\$	0.17	_		\$	0.23
Earnings from continuing operations - Diluted	\$	0.45			\$	0.45	\$ 0.26	=		\$	0.29	\$	0.17	=		\$	0.23
Weighted average shares outstanding - Basic		67.5				67.5	67.6				67.6		89.4				89.4
Weighted average shares outstanding - Diluted		68.3			_	68.3	68.5				68.5		90.7	_		_	90.7
			-														
Managed Basis Adjustments consist of the follow	ing:		^	(1.0)				~						•			
Below market contract obligation			\$	(10)				\$	6 (10)					\$	_		
Costs associated with the sale of Chemtura AgroSol	utions								1						7 (3)		
Other non-recurring charges Facility closures, severance and related costs				1					1						(3)		
Loss on sale of business				1					_						_		
Pre-tax				(8)	-			-	(9)						4	-	
Adjustment to apply a Managed Basis effective tax	rate			8					11						2		
After-tax			\$	_				\$	5 2					\$	6	-	
Adjusted EBITDA consists of the following:																	
Operating income - GAAP					\$	53				\$	44					\$	35
Below market contract obligation						(10)					(10)						_
Costs associated with the sale of Chemtura AgroSol	utions					—					—						7
Other non-recurring charges											1						(3)
Facility closures, severance and related costs						1											
Loss on sale of business						1					25						20
Operating income - Managed Basis Depreciation and amortization - Managed Basis						45 22					35 23						39 24
Non-cash share-based compensation expense						3					23						24
Adjusted EBITDA					\$	70				\$	61					\$	66
Myushu DD1DA					ψ	70			:	Ψ	01					φ	00

CHEMTURA CORPORATION GAAP and Managed Basis Segment Net Sales and Operating Income (Unaudited)

(In millions of dollars)

	Quarter Ended September 30, 2015							Quart	ter	ended June 30	0, 2015	Quarter Ended September 30, 2014							
	GA	АР		Ianaged Basis justments	N	/Ianaged Basis	G	AAP		Managed Basis djustments	Managed Basis	6	GAAP		Managed Basis ljustments		naged asis		
NET SALES	_			,			_			- <u>j</u>		_			3				
Industrial Performance Products	\$	226	\$	_	\$	226	\$	230	\$	— \$	5 230	\$	247	\$	_	\$	247		
Industrial Engineered Products		181		_		181		197		_	197		198		_		198		
Agrochemical Manufacturing		37		(10)		27		37		(10)	27		113		_		113		
Total net sales	\$	444	\$	(10)	\$	434	\$	464	\$	(10) \$	6 454	\$	558	\$	_	\$	558		
OPERATING INCOME	_						_					_							
Industrial Performance Products	\$	37	\$	_	\$	37	\$	38	\$	— \$	5 38	\$	28	\$	_	\$	28		
Industrial Engineered Products		24		1		25		15		1	16		5		1		6		
Agrochemical Manufacturing		9		(10)		(1)		10		(10)	_		20		_		20		
Segment operating income		70		(9)		61	_	63		(9)	54	_	53		1		54		
General corporate expense, including amortization		(15)		(1)		(16)	_	(19)			(19)	_	(18)	,	3		(15)		
Facility closures, severance and related costs		(1)		1		_		_		_	_				_		—		
Loss on sale of business		(1)		1		_		_		_	_				_		_		
Total operating income	\$	53	\$	(8)	\$	45	\$	44	\$	(9) \$	\$ 35	\$	35	\$	4	\$	39		
Managed Basis Adjustments consist of the followin	<u>ıg:</u>		¢	(10)					¢	(10)				¢					
Below market contract obligation			\$	(10)					\$	(10)				\$					
Costs associated with the sale of Chemtura AgroSolu	tions														7				
Other non-recurring charges										1					(3)				
Facility closures, severance and related costs				1															
Loss on sale of business			\$	(8)					\$	(9)				\$	4				
			_	(-)					-	(7				-					
DEPRECIATION AND AMORTIZATION																			
Industrial Performance Products	\$	7	\$	—	\$	7	\$	7	\$	— \$	5 7	\$	7	\$	—	\$	7		
Industrial Engineered Products		11		—		11		12		(1)	11		11		—		11		
Agrochemical Manufacturing		1		—		1		1		—	1		2		—		2		
General corporate expense		3		—		3		4		—	4		4				4		
Total depreciation and amortization	\$	22	\$	_	\$	22	\$	24	\$	(1) \$	\$ 23	\$	24	\$	_	\$	24		
NON-CASH SHARE-BASED COMPENSATION	EXPE	NSE																	
Industrial Performance Products					\$	_				\$	5 1					\$	_		
Industrial Engineered Products						_					1						_		
Agrochemical Manufacturing						_					_						1		
General corporate expense						3					1						2		
Total non-cash share-based compensation expense					\$	3				\$	\$ 3					\$	3		
Adjusted EBITDA by Segment:																			
Industrial Performance Products					\$	44				\$	5 46					\$	35		
Industrial Engineered Products					Ŷ	36				4	28					*	17		
Agrochemical Manufacturing											1						23		
General corporate expense						(10)					(14)						(9)		
Adjusted EBITDA					\$	70				5						\$	66		
Aujusiud EDITDA					¢	/0					01				:	φ	00		